The role of antifungal susceptibility testing in the therapy of candidiasis

Diagnostic Microbiology and Infectious Disease

Volumn 48, Issue 3, 2004, Pages 153-160

  Hospenthal, Duane R ^a   Murray, Clinton K ^a   Rinaldi, Michael G ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antifungal; Candidiasis; Susceptibility testing

Indexed keywords

ABLECET; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; GLUCOSE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DEVICE; DILUTION; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIVITY; FORECASTING; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INOCULATION; LONG TERM CARE; MEDICAL TECHNOLOGY; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MOUTH INFECTION; MUCOSA; NONHUMAN; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; SPECTROPHOTOMETRY; STANDARDIZATION; THERAPY RESISTANCE; THRUSH; TREATMENT FAILURE;

EID: 1542509560     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2003.10.003     Document Type: Article

References (41)

1. Arendrup M., Lundgren B., Jensen I.M., Hansen B.S., Frimodt-Moller N. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J Antimicrob Chemother. 47:2001;521-526.
2. Arikan S., Gur D., Akova M. Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients. Mycoses. 40:1997;291-296.
3. Arikan S., Akova M., Hayran M., Ozdemir O., Erman M., Gur D., Unal S. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin Infect Dis. 26:1998;903-908.
4. Barry A.L., Pfaller M.A., Brown S.D., Espinel-Ingroff A., Ghannoum M.A., Knapp C., Rennie R.P., Rex J.H., Rinaldi M.G. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol. 38:2000;3457-3459.
5. Barry A.L., Pfaller M.A., Rennie R.P., Fuchs P.C., Brown S.D. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 46:2002;1781-1784.
6. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998 comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A. reference method. J Clin Microbiol. 39:2001;4181-4183.
7. Chryssanthou E., Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol. 40:2002;3841-3844.
8. Clancy C.J., Nguyen M.H. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother. 43:1999;1289-1290.
9. Cuenca-Estrella, M., Moore, C. B., Barchiesi, F., Bille, J., Chryssanthou, E., Denning, D. W., Donnelly, J. P., Dromer, F., Dupont, B., Rex, J. H., Richardson, M. D., Sancak, B., Verweij, P. E., Rodríguez-Tudela, J. L. and the AFST Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Clin Microbiol Infect 9, 467-474
10. Deresinski S.C., Stevens D.A. Caspofungin. Clin Infect Dis. 36:2003;1445-1457.
11. Gottfredsson M., Jessup C.J., Cox G.M., Perfect J.R., Ghannoum M.A. Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B. Antimicrob Agents Chemother. 45:2001;3231-3233.
12. Jessup C., Reyes G., Fothergill A., McCarthy D., Rinaldi M., Messer S., Pfaller M., Ghannoum M. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B a multicenter study. J Chemother. 12:2000;22-29.
13. Koc A.N., Gokahmetoglu S., Oguzkaya M. Comparison of Etest with the broth microdilution method in susceptibility testing of yeast isolates against four antifungals. Mycoses. 43:2000;293-297.
14. Kovacicova G., Krupova Y., Lovaszova M., Roidova A., Trupl J., Liskova A., Hanzen J., Milosovic P., Lamosova M., Macekova L., Szovenyiova Z., Purgelova A., Obertik T., Bille J., Krcmery V. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother. 6:2000;216-221.
15. Krcmery V., Barnes A.J. Non-albicans Candida spp. causing fungaemia pathogenicity and antifungal resistance. J Hosp Infect. 50:2002;243-260.
16. Kuhn D.M., George T., Chandra J., Mukherjee P.K., Ghannoum M.A. Antifungal susceptibility of Candida biofilms unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 46:2002;1773-1780.
17. Lee S.C., Fung C.P., Huang J.S., Tsai C.J., Chen K.S., Chen H.Y., Lee N., See L.C., Shieh W.B. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother. 44:2000;2715-2718.
18. Martín-Mazuelos E., Gutiérrez M.J., Aller A.I., Bernal S., Martínez M.A., Montero O., Quindóz G. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp. J Antimicrob Chemother. 43:1999;477-481.
19. Matar M.J., Ostrosky-Zeichner L., Paetznick V.L., Rodriguez J.R., Chen E., Rex J.H. Correlation between E-Test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother. 47:2003;1647-1651.
20. Maxwell M.J., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Diekema D.J., Pfaller M.A., International Fungal Surveillance Participant Group. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol. 41:2003;1087-1090.
21. Morace, G., Amato, G., Bistoni, F., Fadda, G., Marone, P., Montagna, M. T., Oliveri, S., Polonelli, L., Rigoli, R., Muncuso, I., La Face, S., Masucci, L., Romano, L., Napoli, C., Tatò, D., Buscema, M. G., Belli, C. M. C., Piccirillo, M. M., Conti, S., Covan, S., Fanti, F., Cavanna, C., D'Alò, F., & Pitzurra, L. (2002). Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A. broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 40, 2953-2958
22. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA. NCCLS document M27-A.
23. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 2002;National Committee for Clinical Laboratory Standards, Wayne, PA. NCCLS document M27-A2.
24. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts; proposed guideline. 2003;National Committee for Clinical Laboratory Standards, Wayne, PA. NCCLS document M44-P.
25. Nguyen M.H., Clancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R., Sutton D.A., Rinaldi M.G. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis. 177:1998;425-430.
26. Ostrosky-Zeichner L., Marr K.A., Rex J.H., Cohen S.H. Amphotericin B time for a new "gold standard" Clin Infect Dis. 37:2003;415-425.
27. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., Messer S.A. International surveillance of bloodstream infections due to Candida species frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 39:2001;3254-3259.
28. Pfaller M.A., Diekema D.J., Messer S.A., Hollis R.J., Jones R.N. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3, 959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 47:2003;1068-1071.
29. Pfaller M.A., Messer S.A., Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis. 32:1998;223-227.
30. Pfaller M.A., Messer S.A., Houston A., Mills K., Bolmstrom A., Jones R.N. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol. 38:2000;3715-3717.
31. Pfaller M.A., Messer S.A., Karlsson A., Bolmstrom A. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol. 36:1998;2586-2589.
32. Pfaller M.A., Yu W.L. Antifungal susceptibility testing. New technology and clinical applications. Infect Dis Clin North Am. 15:2001;1227-1261.
33. Pina-Vaz C., Sansonetty F., Rodrigues A.G., Costa-Oliveira S., Tavares C., Martinez-de-Oliveira J. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect. 7:2001;609-618.
34. Posteraro B., Romano L., Sanguinetti M., Masucci L., Morace G., Fadda G. Commercial systems for fluconazole susceptibility testing of yeasts comparison with the broth microdilution method. Diagn Microbiol Infect Dis. 38:2000;29-36.
35. Powderly W.G., Kobayashi G.S., Herzig G.P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 84:1988;826-832.
36. Rex J.H., Pfaller M.A., Barry A.L., Nelson P.W., Webb C.D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 39:1995;40-44.
37. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Odds F.C., Rinaldi M.G., Walsh T.J., Barry A.L. Development of interpretive breakpoints for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 24:1997;235-247.
38. Rex J.H., Pfaller M.A., Rinaldi M.G., Polak A., Galgiani J.N. Antifungal susceptibility testing. Clin Microbiol Rev. 6:1993;367-381.
39. Safdar A., Chaturvedi V., Cross E.W., Park S., Bernard E.M., Armstrong D., Perlin D.S. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother. 45:2001;2129-2133.
40. Vandenbossche I., Vaneechoutte M., Vandevenne M., De Baere T., Verschraegen G. Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory. J Clin Microbiol. 40:2002;918-921.
41. Wenisch C., Moore C.B., Krause R., Presterl E., Pichna P., Denning D.W. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol. 39:2001;2458-2462.